AKT1 and hepatocellular carcinoma: In summary, the present data indicate that, in the AKT/c-MET preclinical HCC model, PD901 and MLN0128 monotherapy led to progressive disease, although HCC grew at a slower rate, whereas combined PD901/MLN0128 treatment induced a stable disease.